Eric Russell, DO
Rheumatology · Wynnewood, PANPI 1013243401
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $429 of the $680 with a category attached, or 63.1%. 8 manufacturers reported payments, led by Johnson & Johnson at 37.8% of the total. Reporting peaked in 2021 at $248 and has fallen 93.4% since, to $16 in 2025. That places this record below the midpoint for rheumatology clinicians in PA, where the typical reported total is $1,951.
Across 26 payments — averaging $26.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$257
- Amgen$168
- Pacira Therapeutics, Inc.$94
- Pfizer$88
- GSK$22
- Novartis$19
- plus $32 from 2 others
Across 4 payments — averaging $13,859 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bioverativ Therapeutics Inc.$41K
- Sanofi US Services Inc.$15K
What the payments were for
- Food & beverage$42963%
- Education$25137%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 7 | $257 |
| Amgen(2 entities) | 9 | $168 |
| Pacira Therapeutics, Inc. | 1 | $94 |
| Pfizer | 5 | $88 |
| GSK | 1 | $22 |
| Novartis | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| AstraZeneca | 1 | $12 |
How this compares
$680 in reported general payments places this provider in the 35th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 42 | $601,119 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 40 | $290,788 |
| Enbrel SureclickEtanercept | 22 | $199,141 |
| Xeljanz XrTofacitinib Citrate | 22 | $154,503 |
| Hydroxychloroquine Sulfate | 210 | $15,438 |
| MethotrexateMethotrexate Sodium | 156 | $5,723 |
| Gabapentin | 138 | $3,579 |
| Leflunomide | 51 | $2,947 |
| Duloxetine Hcl | 48 | $2,658 |
| Prednisone | 252 | $2,272 |
| Celecoxib | 45 | $1,459 |
| Pregabalin | 52 | $1,357 |
| Colchicine | 13 | $1,054 |
| Alendronate Sodium | 39 | $622 |
| Methylprednisolone | 55 | $420 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Wynnewood
- Gary GordonWynnewood$95K
- Tanya HarariWynnewood$27K
- Thomas HarderWynnewood$24K
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
- Alan KivitzDuncansville$936K
- Paula HerringNewtown Square$920K
- Rohit AggarwalPittsburgh$810K
- Frederick MurphyDuncansville$494K
- Peter MerkelRadnor$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.